Guggenheim analyst Eddie Hickman lowered the firm’s price target on Outlook Therapeutics (OTLK) to $8 from $10 and keeps a Buy rating on the shares after having caught up with management following the company’s Q2 earnings release. The cash position continues to be an overhang, but management is confident they have a runway to get to the Lytenava PDUFA date of August 27, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Biotech Alert: Searches spiking for these stocks today
- Outlook Therapeutics reports Q2 EPS (40c), consensus (55c)
- Outlook Therapeutics Approves Retention Incentive for CFO
- Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010
- Outlook Therapeutics files to sell 21.72M shares of common stock for holders